Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL 250 share sell ,,, lol ,,,somebody tryin desperatly to shake loose somebodys stops , to get some cheap shares
VFIN is the market maker leading the dumping of shares,,, apparently somebody has a load of shares from when this was low and the're taking the profits now at whatever they can get...VFIN just happens to be the market maker for his broker ...
If you watch L2 ,, you would know that.....
If you don't watch ,,, then learn quick ,,, or don't trade pennies
Thanks ,,,picked up some more cheapies this am ,,,think i'll go take a nap till friday
I smell money ,,,,weeeeeeeeeeee ,,,,, i no nothingggggggggggggg ,,, lol
enough said
• Odyssey will receive the equivalent of 80% of the fair value of artifacts which were primarily used in trade or commerce or were private property and bear no direct connection to the construction, navigation, defense or crew of the ship, such as coins or other cargo
http://finance.yahoo.com/news/Odyssey-Marine-Exploration-pz-3779757118.html?x=0
OMEX learned the hard way on the spanish galeon...salvage laws are salvage laws ...they new this ,,, the loss on the spanish gold was written off in previous 10Q's has no effeffect on their opporations now
Mark Gordon, Odyssey Marine's president, said the ruling would not affect current operations and business plans because all expenses of the project had already been passed through the company's prior profit and loss statements.
He said the company was planning for three shipwreck recoveries in 2012. "The future of Odyssey Marine Explorations has never looked brighter," Gordon said in a statement.
http://www.reuters.com/article/2012/02/18/usa-spain-shipwreck-idUSL2E8DHDOH20120218?feedType=RSS&feedName=industrialsSector&rpc=43
LOL old news OMEX wrote off the spanish gold a long time ago............LOL .... 2.85 in pre-market ,,, what a steal ,,,thank you whoever you are...........
THEY ARE ABOUT READY TOO START THE RECOVERY OF 2 NEW WRECKS OF WHICH THEY ALLREADY HAVE AGREEMENTS IN PLACE.
THEY GET TO KEEP 80 %
WEEEEEEEEEEEEEEEEEEEEE
IMO 8 Dollars a share is coming soon
The news is also on the CHRI site
my bad
1 to 100 and it's 30 cents
penny stocks----buyer beware
lost (.82) cents a share last year on an inventory rightdown ,,,that's what brought this down
Recent insider buys
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335505
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335506
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335499
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335501
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335497
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335498
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8335494
Testing RESISTANCE !!!!!!!!!!!!
$27.00 !!!!!!!!!!!
I have 4 family members with type 2 diabetes ,,,,you have no idea of hoe much this means to us !!!!!!!!!!!!!!
FDA Approves BYDUREON(TM) -- The First and Only Once-Weekly Treatment for Type 2 Diabetes
Last update: 1/27/2012 3:39:00 PM
Provides Glycemic Control in a Once-Weekly Dose
SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (AMLN) and Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON(TM) (exenatide extended-release for injectable suspension) - the first once-weekly treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple clinical settings. BYDUREON will be available in pharmacies nationwide in February.
To view the multimedia assets associated with this release, please visit:
"With BYDUREON, U.S. physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week," said John Buse, M.D., Ph.D., professor of medicine, director of the Diabetes Care Center and chief of the Division of Endocrinology at the University of North Carolina School of Medicine in Chapel Hill. "New treatment options are essential for the millions of adults with type 2 diabetes who continue to struggle to achieve optimal blood sugar control."
The approval of BYDUREON (pronounced by-DUR-ee-on) was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with BYDUREON resulted in improvements in glycemic control with just one dose per week. The approval was also based on clinical experience with BYETTA® (exenatide) injection, a twice-daily form of exenatide that has been available in the U.S. since June 2005 and is used in nearly 80 countries worldwide. BYDUREON uses Alkermes' proprietary technology for long-acting medications to provide a controlled release of exenatide.
"As the first and only once-weekly diabetes treatment, BYDUREON represents an important milestone in Amylin's promise to bring to market innovative therapies to help improve the lives of people with type 2 diabetes," said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. "BYDUREON builds upon the proven benefits of BYETTA, offering significant improvements in glycemic control in a single weekly dose."
In the DURATION-5 head-to-head clinical study, after 24 weeks of treatment, patients taking once-weekly BYDUREON experienced a statistically superior reduction in A1C of 1.6 percentage points from baseline, compared to a reduction of 0.9 percentage points for patients taking BYETTA. A1C is a measure of average blood sugar over three months. Both treatment groups achieved statistically significant weight loss by the end of the study, with an average loss of 5.1 pounds for patients taking BYDUREON and 3.0 pounds for patients taking BYETTA (weight loss was a secondary endpoint).The most frequently reported adverse event in both groups was nausea, reported less frequently by BYDUREON users (14 percent) than by BYETTA users (35 percent). Other common treatment-emergent adverse events in the BYDUREON group included diarrhea, upper respiratory tract infection and injection site nodules. There were no major hypoglycemic events.
BYDUREON has been approved with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of BYDUREON outweigh the risk of acute pancreatitis and the potential risk of medullary thyroid carcinoma. As part of the REMS, Amylin has established a communication plan for healthcare professionals to help minimize these risks. In addition, Amylin will fulfill a number of post-marketing requirements to further assess the impact of BYDUREON on medullary thyroid cancer and cardiovascular disease. More information will be available at .
BYDUREON is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous injection. In the DURATION clinical studies, the delivery system was well accepted by patients and physicians.
ALMN
Shares Outstanding 137,241,585 a/o Jul 25, 2008
Float Not Available
Authorized Shares Not Available
Par Value 0.001
BIG NEWS BYDUREONâ„¢ once a week diabetes drug
get it while it's still cheap
I agree,,,
IJJP>>> 504 selling done ,,, flippers DONE ,,,, READY TO ROCK,,,,last of the cheapies going now !!!!!!
look at the charts ,,,lotta people bought last week at .0004 and .0005 ,,,,looks like normal profit taking to me ,,,,lotta peops dumped early this morning when .001 didn't hold ,,,,but the way it ran up easy on friday is how this stock runs ,,,,
get ready to run again ,,, looks like this stock is in better hands..........
Wanna hint ,,, look at the bid on L2 38 million shares at .0005 ,,,,somebody wants this real bad !!!!!!!!
IJJP Nowhere to go but up now !!!!!
IJJP Nowhere to go buy up now
nowhere to go but up now
runnin out of flippers ,,, buying all i can
I see lotsa Form 4's ,,,, all CODE A .... That means aquired....there are NO CODE D'S (disposed) no insiders are selling,,,,,,,,, SO WHERE IS THIS SUPPOSED DILUTION COMEING FROM ????
LINKS ????
So what's the float now ???
goin up again !!
This is for real !!! NO pump and dump here !!!! Investors holding steady !!!! This can only go up !!!! Nobody cryin shorty !!!! NO DILUTION !!!! GOIN UP GUYS AN DOLLS
At least ya know it's not a pump and dump ,,,this is for real ,,,share holders are holding steady ,,, this can only go up !!!!!! NO DILUTION !!!! Nobody cryin shorty !!!!
ALWAYS SINKS,,,doesn't it,,,rocks just never float
ALWAYS SINKS,,,doesn't it,,,rocks just never float
PMAH reverse merger
PMAH reverse merger
PMAH reverse merger
this is getting real thin,,, get ready to move